Zeno Fratton

Udine, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Unveiling the IL-17 axis: an immunometabolic bridge between psoriasis and metabolic syndrome.

Unveiling the IL-17 axis: an immunometabolic bridge between psoriasis and metabolic syndrome.

Journal: The Journal of dermatological treatment

Published: June 01, 2026

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy.

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy.

Journal: Dermatology and therapy

Published: May 06, 2026

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Journal: Clinical and experimental dermatology

Published: April 12, 2026

Dupilumab-Related Ocular Surface Disease in Atopic Dermatitis: Risk Stratification, Monitoring, and Persistence-Preserving Management.

Dupilumab-Related Ocular Surface Disease in Atopic Dermatitis: Risk Stratification, Monitoring, and Persistence-Preserving Management.

Journal: Journal of clinical medicine

Published: January 29, 2026

Clinical and Functional Determinants of Caregiver Burden in Elderly Patients with Atopic Dermatitis: A Multicentre Cross-Sectional Study.

Clinical and Functional Determinants of Caregiver Burden in Elderly Patients with Atopic Dermatitis: A Multicentre Cross-Sectional Study.

Journal: Clinical, cosmetic and investigational dermatology

Published: November 28, 2025

Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study.

Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study.

Journal: Antibodies (Basel, Switzerland)

Published: July 24, 2025

Predictors of Response to Topical Ruxolitinib in Non-segmental Vitiligo: A Narrative Review.

Predictors of Response to Topical Ruxolitinib in Non-segmental Vitiligo: A Narrative Review.

Journal: The Australasian journal of dermatology

Published: July 24, 2025

Real-World Experience of Guselkumab in the Elderly Population.

Real-World Experience of Guselkumab in the Elderly Population.

Journal: Psoriasis (Auckland, N.Z.)

Published: June 25, 2025

NEVIGRAV Study: A Case-Control Analysis on Changes in Melanocytic Nevi During Pregnancy.

NEVIGRAV Study: A Case-Control Analysis on Changes in Melanocytic Nevi During Pregnancy.

Journal: The Journal of dermatology

Published: May 21, 2025

Management Strategies for Generalised Granuloma Annulare: A Systematic Review of Current and Emerging Therapies.

Management Strategies for Generalised Granuloma Annulare: A Systematic Review of Current and Emerging Therapies.

Journal: The Australasian journal of dermatology

Published: March 17, 2025

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events.

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events.

Journal: Psoriasis (Auckland, N.Z.)

Published: December 26, 2024

Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in HIV-Positive Patients: Insights From Four Italian Centers.

Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in HIV-Positive Patients: Insights From Four Italian Centers.

Journal: The Australasian journal of dermatology

Published: December 19, 2024

Showing 1-12 of 20

Last Updated: 09/26/2026